Cargando…

Synthesis and anticancer activity of dimeric podophyllotoxin derivatives

BACKGROUND: Podophyllotoxin is a potent cytotoxic agent and serves as a useful lead compound for the development of antitumor drugs. Several podophyllotoxin-derived antitumor agents, including etoposide, are currently in clinical use; however, their therapeutic efficacy is often limited due to side...

Descripción completa

Detalles Bibliográficos
Autores principales: Zi, Cheng-Ting, Yang, Liu, Xu, Feng-Qing, Dong, Fa-Wu, Yang, Dan, Li, Yan, Ding, Zhong-Tao, Zhou, Jun, Jiang, Zi-Hua, Hu, Jiang-Miao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186772/
https://www.ncbi.nlm.nih.gov/pubmed/30349193
http://dx.doi.org/10.2147/DDDT.S167382
_version_ 1783362900640923648
author Zi, Cheng-Ting
Yang, Liu
Xu, Feng-Qing
Dong, Fa-Wu
Yang, Dan
Li, Yan
Ding, Zhong-Tao
Zhou, Jun
Jiang, Zi-Hua
Hu, Jiang-Miao
author_facet Zi, Cheng-Ting
Yang, Liu
Xu, Feng-Qing
Dong, Fa-Wu
Yang, Dan
Li, Yan
Ding, Zhong-Tao
Zhou, Jun
Jiang, Zi-Hua
Hu, Jiang-Miao
author_sort Zi, Cheng-Ting
collection PubMed
description BACKGROUND: Podophyllotoxin is a potent cytotoxic agent and serves as a useful lead compound for the development of antitumor drugs. Several podophyllotoxin-derived antitumor agents, including etoposide, are currently in clinical use; however, their therapeutic efficacy is often limited due to side effects and the development of resistance by cancer cells. Previous studies have shown that 4β-1,2,3-triazole derivatives of podophyllotoxin exhibit more potent anticancer activity and better binding to topoisomerase-II than etoposide. The effect of dimerization of such derivatives on the anticancer activity has not been studied. METHODS: Two moieties of podophyllotoxin were linked at the C-4 position via 1,2,3-triazole rings to give a series of novel dimeric podophyllotoxin derivatives. 4β-Azido-substituted podophyllotoxin derivatives (23 and 24) were coupled with various dipropargyl functionalized linkers by utilizing the copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction to provide dimeric products in very good yield. The in vitro anticancer activity of the synthesized compounds was evaluated by MTT assay against a panel of five human cancer cell lines (HL-60, SMMC-7721, A-549, MCF-7, and SW480). The normal BEAS-2B (lung) cell line was also included for study in order to evaluate the cancer selectivity of the most active compound as compared with normal cells. RESULTS: A group of 16 dimeric podophyllotoxin derivatives with different linkers were synthesized and structurally characterized. Most compounds do not show significant cytotoxicity (IC(50) > 40 mM) against all five cancer cell lines. However, one compound (29) which bears a perbutyrylated glucose residue on the glycerol linker is highly potent against all five cancer cell lines tested, with IC(50) values ranging from 0.43 to 3.50 μM. This compound (29) also shows good selectivity towards cancer cell lines as compared with the normal BEAS-2B (lung) cell line, showing selectivity indexes from 4.4 to 35.7. CONCLUSION: The anticancer activity of dimeric podophyllotoxin derivatives is generally speaking not improved as compared to their monomeric counterparts, and the potency of these dimeric derivatives can be largely affected by the nature of the linker between the two moieties. Among the synthesized derivatives, compound 29 is significantly more cytotoxic and selective towards cancer cells than etoposide and cisplatin, which are currently in clinical use. Compound 29 is a promising anticancer drug and needs further studies.
format Online
Article
Text
id pubmed-6186772
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61867722018-10-22 Synthesis and anticancer activity of dimeric podophyllotoxin derivatives Zi, Cheng-Ting Yang, Liu Xu, Feng-Qing Dong, Fa-Wu Yang, Dan Li, Yan Ding, Zhong-Tao Zhou, Jun Jiang, Zi-Hua Hu, Jiang-Miao Drug Des Devel Ther Original Research BACKGROUND: Podophyllotoxin is a potent cytotoxic agent and serves as a useful lead compound for the development of antitumor drugs. Several podophyllotoxin-derived antitumor agents, including etoposide, are currently in clinical use; however, their therapeutic efficacy is often limited due to side effects and the development of resistance by cancer cells. Previous studies have shown that 4β-1,2,3-triazole derivatives of podophyllotoxin exhibit more potent anticancer activity and better binding to topoisomerase-II than etoposide. The effect of dimerization of such derivatives on the anticancer activity has not been studied. METHODS: Two moieties of podophyllotoxin were linked at the C-4 position via 1,2,3-triazole rings to give a series of novel dimeric podophyllotoxin derivatives. 4β-Azido-substituted podophyllotoxin derivatives (23 and 24) were coupled with various dipropargyl functionalized linkers by utilizing the copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction to provide dimeric products in very good yield. The in vitro anticancer activity of the synthesized compounds was evaluated by MTT assay against a panel of five human cancer cell lines (HL-60, SMMC-7721, A-549, MCF-7, and SW480). The normal BEAS-2B (lung) cell line was also included for study in order to evaluate the cancer selectivity of the most active compound as compared with normal cells. RESULTS: A group of 16 dimeric podophyllotoxin derivatives with different linkers were synthesized and structurally characterized. Most compounds do not show significant cytotoxicity (IC(50) > 40 mM) against all five cancer cell lines. However, one compound (29) which bears a perbutyrylated glucose residue on the glycerol linker is highly potent against all five cancer cell lines tested, with IC(50) values ranging from 0.43 to 3.50 μM. This compound (29) also shows good selectivity towards cancer cell lines as compared with the normal BEAS-2B (lung) cell line, showing selectivity indexes from 4.4 to 35.7. CONCLUSION: The anticancer activity of dimeric podophyllotoxin derivatives is generally speaking not improved as compared to their monomeric counterparts, and the potency of these dimeric derivatives can be largely affected by the nature of the linker between the two moieties. Among the synthesized derivatives, compound 29 is significantly more cytotoxic and selective towards cancer cells than etoposide and cisplatin, which are currently in clinical use. Compound 29 is a promising anticancer drug and needs further studies. Dove Medical Press 2018-10-09 /pmc/articles/PMC6186772/ /pubmed/30349193 http://dx.doi.org/10.2147/DDDT.S167382 Text en © 2018 Zi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zi, Cheng-Ting
Yang, Liu
Xu, Feng-Qing
Dong, Fa-Wu
Yang, Dan
Li, Yan
Ding, Zhong-Tao
Zhou, Jun
Jiang, Zi-Hua
Hu, Jiang-Miao
Synthesis and anticancer activity of dimeric podophyllotoxin derivatives
title Synthesis and anticancer activity of dimeric podophyllotoxin derivatives
title_full Synthesis and anticancer activity of dimeric podophyllotoxin derivatives
title_fullStr Synthesis and anticancer activity of dimeric podophyllotoxin derivatives
title_full_unstemmed Synthesis and anticancer activity of dimeric podophyllotoxin derivatives
title_short Synthesis and anticancer activity of dimeric podophyllotoxin derivatives
title_sort synthesis and anticancer activity of dimeric podophyllotoxin derivatives
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186772/
https://www.ncbi.nlm.nih.gov/pubmed/30349193
http://dx.doi.org/10.2147/DDDT.S167382
work_keys_str_mv AT zichengting synthesisandanticanceractivityofdimericpodophyllotoxinderivatives
AT yangliu synthesisandanticanceractivityofdimericpodophyllotoxinderivatives
AT xufengqing synthesisandanticanceractivityofdimericpodophyllotoxinderivatives
AT dongfawu synthesisandanticanceractivityofdimericpodophyllotoxinderivatives
AT yangdan synthesisandanticanceractivityofdimericpodophyllotoxinderivatives
AT liyan synthesisandanticanceractivityofdimericpodophyllotoxinderivatives
AT dingzhongtao synthesisandanticanceractivityofdimericpodophyllotoxinderivatives
AT zhoujun synthesisandanticanceractivityofdimericpodophyllotoxinderivatives
AT jiangzihua synthesisandanticanceractivityofdimericpodophyllotoxinderivatives
AT hujiangmiao synthesisandanticanceractivityofdimericpodophyllotoxinderivatives